Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06475599 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Interventions: Anlotinib hydrochloride capsule + TQB2450 injection (Drug), Paclitaxel or Albumin-bound paclitaxel or Doxorubicin or Liposomal doxorubicin… to Anlotinib hydrochloride capsule + TQB2450 injection (Drug), Chemotherapy drug (Drug)v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To demonstrate that anlotinib hydrochloride capsules combined with TQB2450 injection can significantly prolong progression-free survival (PFS) compared with chemotherapy in patients with recurrent or metastatic endometrial cancer that is non- microsatellite instability high (non-MSI-H) or DNA mismatch repair deficient (non-dMMR).
Trial Details
NCT Number NCT06475599
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Endometrial Cancer
Enrollment 420 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov